TELO Telomir Pharmaceuticals, Inc. Common Stock
USHealthcareAs of 2026-08-17
Why TELO matters now
Telomir Pharmaceuticals, Inc. Common Stock (TELO) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.06 with -2.75% on the session and $72.9M in market capitalization; recent performance reads 1-month +16.39% and YTD +6.77%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-990.9K, and EPS of $-0.03. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.4%.
The latest indexable market news headline is "Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?" from Defense World.
Additional event context on this page matters because analyst consensus is available with a median target of $—; recent insider activity includes Mushak Andriy filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
9.84
P/S
0.00
EV/EBITDA
-4.69
DCF Value
$0.21
FCF Yield
-9.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-201.2%
ROA
-159.3%
ROIC
-181.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-990.9K | $-0.03 |
| Q4 2025 | $0.00 | $-2.1M | $-0.06 |
| FY 2025 | $0.00 | $-10.4M | $-0.33 |
| Q3 2025 | $0.00 | $-1.1M | $-0.03 |
Analyst Ratings
Consensus
—
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.23
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.